Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, has chosen MedPharm as its expert partner to develop new topical formulations of the Company's novel XF-platform compounds, it is reported today.
The new topical formulations are part of the company's second clinical programme to address the global problem of anti-microbial resistance
The XF platform has already delivered a Phase two ready candidate, XF-73 nasal gel, for the prevention of post-surgical infections, that is to commence in Phase 2b testing in 2019. MedPharm will develop new formulations containing Destiny Pharma's XF-platform compounds for the treatment of various topically treated infections, including diabetic foot ulcers and ophthalmic infections.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes